

# Jeremy A Rassen Scd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9273743/publications.pdf>

Version: 2024-02-01

72  
papers

6,724  
citations

94269

37  
h-index

91712

69  
g-index

77  
all docs

77  
docs citations

77  
times ranked

9208  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. <i>Epidemiology</i> , 2009, 20, 512-522.	1.2	870
2	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. <i>Science</i> , 2020, 370, .	6.0	508
3	One-to-many propensity score matching in cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 69-80.	0.9	373
4	The Comparative Safety of Analgesics in Older Adults With Arthritis. <i>Archives of Internal Medicine</i> , 2010, 170, 1968.	4.3	348
5	Confounding Control in Healthcare Database Research. <i>Medical Care</i> , 2010, 48, S114-S120.	1.1	291
6	Instrumental variable methods in comparative safety and effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 537-554.	0.9	288
7	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. <i>JAMA Internal Medicine</i> , 2021, 181, 672.	2.6	236
8	The Comparative Safety of Opioids for Nonmalignant Pain in Older Adults. <i>Archives of Internal Medicine</i> , 2010, 170, 1979.	4.3	212
9	Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. <i>Circulation</i> , 2009, 120, 2322-2329.	1.6	210
10	Metrics for covariate balance in cohort studies of causal effects. <i>Statistics in Medicine</i> , 2014, 33, 1685-1699.	0.8	207
11	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. <i>American Journal of Epidemiology</i> , 2011, 174, 1213-1222.	1.6	205
12	Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. <i>European Heart Journal</i> , 2012, 33, 1893-1901.	1.0	178
13	Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 777-790.	2.3	157
14	Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. <i>American Journal of Epidemiology</i> , 2011, 173, 1404-1413.	1.6	149
15	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1226-1232.	2.4	146
16	Graphical Depiction of Longitudinal Study Designs in Health Care Databases. <i>Annals of Internal Medicine</i> , 2019, 170, 398.	2.0	140
17	Instrumental Variable Analysis for Estimation of Treatment Effects With Dichotomous Outcomes. <i>American Journal of Epidemiology</i> , 2008, 169, 273-284.	1.6	132
18	Matching by Propensity Score in Cohort Studies with Three Treatment Groups. <i>Epidemiology</i> , 2013, 24, 401-409.	1.2	132

#	ARTICLE	IF	CITATIONS
19	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1018-1032.	0.9	126
20	Instrumental variables II: instrumental variable application in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1233-1241.	2.4	108
21	Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF- $\alpha$ Blockade with Nonbiologic DMARDs. <i>American Journal of Medicine</i> , 2013, 126, 730.e9-730.e17.	0.6	94
22	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. <i>Computational Statistics and Data Analysis</i> , 2014, 72, 219-226.	0.7	85
23	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3390-3398.	6.7	83
24	Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 41-49.	0.9	81
25	Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. <i>Clinical Epidemiology</i> , 2019, Volume 11, 1-15.	1.5	78
26	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017, 20, 1009-1022.	0.1	70
27	Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. <i>BMJ</i> , The, 2013, 347, f5416-f5416.	3.0	68
28	Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 697-709.	0.9	65
29	The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 135-144.	2.3	58
30	Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 561-572.	1.0	56
31	Confounding Adjustment in Comparative Effectiveness Research Conducted Within Distributed Research Networks. <i>Medical Care</i> , 2013, 51, S4-S10.	1.1	55
32	Evaluating the Validity of an Instrumental Variable Study of Neuroleptics. <i>Medical Care</i> , 2007, 45, S116-S122.	1.1	54
33	Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. <i>Epidemiology</i> , 2017, 28, 237-248.	1.2	54
34	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1813-1818.	0.5	50
35	Design considerations in an active medical product safety monitoring system. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 32-40.	0.9	46
36	Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. <i>Cmaj</i> , 2021, 193, E10-E18.	0.9	45

#	ARTICLE	IF	CITATIONS
37	Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 848-857.	0.9	43
38	Durability of the Single-Dose Ad26.COVS.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge. <i>JAMA Network Open</i> , 2022, 5, e222959.	2.8	42
39	Active Safety Monitoring of Newly Marketed Medications in a Distributed Data Network: Application of a Semi-Automated Monitoring System. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 80-86.	2.3	41
40	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. <i>Statistics in Medicine</i> , 2015, 34, 753-781.	0.8	36
41	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , 2012, 12, 180.	1.4	33
42	Effects of expanding the look-back period to all available data in the assessment of covariates. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 890-899.	0.9	33
43	Comparative Effectiveness of Preventative Therapy for Venous Thromboembolism After Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 590-596.	1.4	32
44	Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics. <i>Medical Care</i> , 2010, 48, S83-S89.	1.1	30
45	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1199-1209.	0.9	29
46	Active Safety Monitoring of New Medical Products Using Electronic Healthcare Data. <i>Epidemiology</i> , 2012, 23, 238-246.	1.2	29
47	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 816-828.	2.3	29
48	Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 675-683.	0.9	21
49	Myers et al. Respond to "Understanding Bias Amplification". <i>American Journal of Epidemiology</i> , 2011, 174, 1228-1229.	1.6	21
50	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 619-627.	0.9	21
51	Prospective Cohort Studies of Newly Marketed Medications. <i>Epidemiology</i> , 2014, 25, 126-133.	1.2	17
52	Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel. <i>Drug Safety</i> , 2014, 37, 151-161.	1.4	15
53	Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 90-98.	0.9	13
54	Adjuvant vancomycin for antibiotic prophylaxis and risk of <i>Clostridium difficile</i> infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 472-478.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. <i>Drug Safety</i> , 2012, 35, 407-416.	1.4	12
56	Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 1442-1452.	0.5	12
57	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1453-1462.	2.2	12
58	Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 109-111.	0.6	11
59	Optimal Matching Ratios in Drug Safety Surveillance. <i>Epidemiology</i> , 2014, 25, 772-773.	1.2	11
60	An Event-Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 631-639.	0.9	10
61	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , 2015, 38, 1075-1082.	1.4	10
62	Categorization of COVID-19 severity to determine mortality risk. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 721-728.	0.9	10
63	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0248128.	1.1	9
64	Emerging Analytical Techniques for Comparative Effectiveness Research. <i>American Journal of Kidney Diseases</i> , 2013, 61, 13-17.	2.1	8
65	Letter to the editor. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1110-1111.	0.9	6
66	Single-arm oncology trials and the nature of external controls arms. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1053-1066.	0.6	6
67	Incorporating Linked Healthcare Claims to Improve Confounding Control in a Study of In-Hospital Medication Use. <i>Drug Safety</i> , 2015, 38, 589-600.	1.4	5
68	Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile. <i>Drugs - Real World Outcomes</i> , 2020, 7, 221-227.	0.7	2
69	Outcomes in the Era of Bare-Metal Stents vs the Era of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 33.	3.8	0
70	Response to Letter Regarding Article, "Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome". <i>Circulation</i> , 2010, 122, .	1.6	0
71	Response to commentary by Marcus and Gibbons. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 713-713.	0.9	0
72	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1694-1695.	2.2	0